Liminatus Pharma Regains Nasdaq Compliance with Higher Stock Price
News related to:Liminatus Pharma, Inc · 1 min read
FULLERTON, Calif., Sept. 29, 2026 /CourierPR/ -- Liminatus Pharma, Inc. has regained compliance with Nasdaq's minimum bid price rule, marking a significant milestone for the biotechnology company. On September 24, 2026, the company received a notice from Nasdaq, confirming that the closing bid price of its common stock had been above $1.00 for 13 consecutive trading days, specifically from August 21, 2026, to September 9, 2026. This achievement comes after the company faced a challenging period, having received a notice from Nasdaq on January 15, 2026, indicating that the closing bid price of its common stock had been below $1.00 for 30 consecutive business days.
The company's journey to regain compliance involved a series of strategic steps. Following the initial notice, Liminatus Pharma was transferred to The Nasdaq Capital Market effective August 4, 2026, with an extension granted to demonstrate compliance with the applicable minimum bid price requirement by September 3, 2026. To facilitate this process, the company took action on August 20, 2026, by effecting a 1-for-50 reverse stock split. This action was designed to increase the stock price and bring it in line with Nasdaq's requirements.
Liminatus Pharma is a biotechnology company focused on developing innovative immuno-oncology and cell therapy candidates. The company's portfolio includes IBA101, a next-generation anti-CD47 monoclonal antibody, as well as oncology-focused cellular therapy programs, including IBC101, a CD19xCD22 bivalent CAR-T candidate for B-cell malignancies. The company's commitment to advancing differentiated therapeutic approaches designed to address unmet needs in cancer treatment underscores its dedication to innovation and patient care.
The company's ability to regain compliance with Nasdaq's minimum bid price rule is a testament to its resilience and strategic planning. This achievement not only ensures the company's continued listing on Nasdaq but also provides a strong foundation for future growth and development. Liminatus Pharma remains focused on advancing its pipeline of innovative therapies to improve patient outcomes in the field of oncology.